Investigating how immune cell signaling affects cancer treatment with T cells
Official title: Death receptor signaling as an immune checkpoint in tumor-specific iPSC-T cell function
Funded at University of California Los Angeles · NIH-11050923 · Data updated 2026-11-12
This study is looking at how special immune cells made from stem cells can be better used to fight cancer, with the goal of creating treatments that work longer and more effectively for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | December 5, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $569,863 |
| NIH project number | 1R37CA290185-01A1 |
| Project ID | NIH-11050923 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with acute B-lymphocytic leukemia or other cancers that may benefit from adoptive T cell therapy.
✕Less likely to help
Patients with solid tumors that do not respond to T cell therapies or those who are not eligible for adoptive T cell transfer may not benefit from this research.
What this research studies
This research focuses on improving cancer therapies by using T cells derived from induced pluripotent stem cells (iPSCs). The team aims to understand how these T cells interact with tumors and why they may not persist effectively in the body. By exploring the signaling pathways that limit the effectiveness of these cells, the researchers hope to enhance their ability to target and kill cancer cells. Patients may benefit from more effective and durable cancer treatments through this innovative approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the power of engineered T cells to persist longer and fight tumors more effectively.
How similar studies have gone: Previous research has shown promise in using engineered T cells for cancer treatment, indicating that this approach may lead to significant advancements in the field.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Seet, Christopher — University of California Los Angeles
- Study coordinator: Seet, Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.